Citius Pharmaceuticals Launches LYMPHIR, Stock Surges

Written by Emily J. Thompson, Senior Investment Analyst

Source: Benzinga

Updated: Dec 24 2025

0mins

Should l Buy CTXR?

Source: Benzinga

Citius Pharmaceuticals Inc's stock surged by 10.58% in pre-market trading as it crossed above the 5-day SMA, reflecting positive investor sentiment.

This surge is attributed to the successful launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphoma, which is expected to generate significant revenue with an initial market potential exceeding $400 million. The launch marks a pivotal moment for Citius, transitioning from pre-revenue to revenue-generating status, and is supported by strategic financing of $36 million to bolster its commercialization efforts.

The implications of this launch are substantial, as it not only enhances Citius's market position but also addresses an unmet need in oncology treatment. The company's proactive engagement with the FDA and plans for international market expansion further indicate a strong growth trajectory.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CTXR?" and start using high-conviction signals backed by rigorous historical data.

CTXR

$0.7547+Infinity%1D

Analyst Views on CTXR

About CTXR

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

UiPath to Join S&P Midcap 400 Index Effective January 2, 2026

Dec 27 2025Yahoo Finance

Market Focus: UiPath Inc. announced it will join the S&P Midcap 400 Index on January 2, 2026, replacing Synovus Financial Corp., a move expected to enhance the company's visibility and investor confidence.
Stock Price Surge: Following this announcement, UiPath shares rose 6.8% to $17.05 in after-hours trading, reflecting market optimism regarding its future performance.
FDA Approval: Agios Pharmaceuticals' AQVESME™ (mitapivat) received FDA approval for treating anemia in adults with alpha- or beta-thalassemia, although its stock fell 1.4%, this approval could pave the way for future sales growth.
Stock Buyback Plan: Ramaco Resources announced a $100 million stock repurchase plan, with shares jumping 7.1% in after-hours trading, indicating the company's confidence in its value and potentially attracting more investor interest.

U.S. Stocks Rise with Dow Jones Surging Over 200 Points

Dec 24 2025Benzinga

Dow Jones Surge: The Dow Jones index rose over 200 points on Wednesday, increasing by 0.48% to close at 48,673.55, indicating improved investor sentiment that could drive further market gains.
Jobless Claims Decline: Initial jobless claims in the U.S. fell by 10,000 to 214,000 for the week ending December 20, below market estimates of 223,000, suggesting ongoing labor market improvement that supports economic recovery.
Strong Stock Performance: Edgewise Therapeutics (NASDAQ:EWTX) shares surged 21% to $26.36 following positive updates from its ongoing CIRRUS-HCM Phase 2 trial, highlighting the company's potential in the biopharmaceutical sector.
Diverse Company Growth: Multi Ways Holdings (NYSE:MWG) saw its stock price jump 62% to $0.41 after reporting a year-over-year increase in H1 EPS, reflecting strong growth momentum in its business operations.

U.S. Initial Jobless Claims Drop to 214,000, Beating Estimates

Dec 24 2025Benzinga

Jobless Claims Decline: U.S. initial jobless claims fell by 10,000 to 214,000 for the week ending December 20, surpassing market expectations of 223,000, indicating labor market resilience which could positively impact economic recovery.
Market Performance Rebounds: The Dow Jones index rose over 100 points, up 0.28% to 48,576.79, reflecting improved investor sentiment that may drive more capital into the stock market.
Sector Performance Divergence: Consumer staples stocks increased by 0.6%, while communication services stocks fell by 0.2%, indicating varied market reactions across sectors, prompting investors to monitor industry dynamics for optimal portfolio adjustments.
International Market Fluctuations: Asian markets closed mixed, with Japan's Nikkei 225 down 0.14% and China's Shanghai Composite up 0.53%, suggesting ongoing global economic uncertainties are still influencing market sentiment.

Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million

Dec 24 2025Benzinga

Significant Revenue Growth: Multi Ways Holdings reported net revenue of $26.44 million for the six months ended June 30, representing an impressive 87.65% increase from $14.09 million in the same period last year, indicating strong market performance and growth potential.
Positive Market Reaction: Following the earnings announcement, Multi Ways Holdings' stock surged 62.86%, reflecting investor confidence and optimism regarding the company's future prospects and performance.
Clear Strategic Positioning: The company's revenue growth and expansion in Singapore highlight its strategic focus on the Asia-Pacific market, aiming to enhance competitiveness through ongoing market penetration and innovation.
Increased Investor Confidence: With the significant improvement in performance, the company is expected to attract more investor attention, further driving stock price appreciation and strengthening its market position.